Trial Search Results

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

A Phase 1b/2, multicenter, open-label study designed to evaluate the efficacy and safety of ACP-196 in subjects with recurrent GBM who have progressed after 1 or 2 prior systemic treatment regimens.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Acerta Pharma BV

Stanford Investigator(s):


  • Drug: ACP-196


Phase 1/Phase 2


Inclusion Criteria:

   - Histologically confirmed GBM at first or second recurrence after concurrent or
   adjuvant chemotherapy or radiotherapy (must have received temozolomide).

   - Radiographic demonstration of disease progression by MRI following prior therapy.

   - ECOG performance status ≤ 2.

   - Life expectancy ≥ 12 weeks.

   - Completion of all prior anticancer therapy before first ACP-196 dose.

Exclusion Criteria:

   - Three or more prior lines of systemic therapy for GBM.

   - Significant cardiovascular disease.

   - Evidence of bleeding diathesis or coagulopathy.

   - Requires urgent palliative intervention for primary disease.

   - History of stroke or clinically significant intracranial hemorrhage within 6 months
   before first dose of study drug.

   - Breastfeeding or pregnant.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting